# Cipla

Source: https://onco.cc/companies/cipla/  
OnCo record `cipla` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The Mumbai generics maker famous for a one-dollar-a-day HIV regimen, which sells oncology generics across India and Africa and in 2026 partnered with ImmunoACT to take Indian CAR-T therapy to Africa.

## Summary

Cipla was founded in Mumbai in 1935 by Khwaja Abdul Hamied and is India's third-largest drug producer. Its reputation rests on the early-2000s antiretroviral combination it sold for about 300 dollars a year against 12,000 dollars for the branded regimen, and it has applied the same approach to oncology generics and biosimilars for India and emerging markets. In 2026 ImmunoACT announced a collaboration with Cipla to distribute NexCAR19 in South Africa, Algeria and Morocco, the first export of an Indian CAR-T therapy.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Mumbai
- Type: pharma
- Website: https://www.cipla.com
- Ticker: CIPLA.NS

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Cipla
- Official website: https://www.cipla.com

## Connected records

- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Chemotherapy](https://onco.cc/fronts/chemotherapy/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Oral solid dose manufacturing (tablets and capsules)](https://onco.cc/technologies/oral-solid-dose-manufacturing/), [Small-molecule API synthesis](https://onco.cc/technologies/small-molecule-api-synthesis/)
- drugs: [Talicabtagene autoleucel](https://onco.cc/drugs/talicabtagene-autoleucel/)
- companies: [ImmunoACT](https://onco.cc/companies/immunoact/)
- bottlenecks: [Most of the world has almost no cancer care](https://onco.cc/bottlenecks/b-global-access/), [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/)
- terms: [Nexavar compulsory licence (India, 2012)](https://onco.cc/terms/nexavar-compulsory-licence/)
- roadmaps: [Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation](https://onco.cc/roadmaps/global-access-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/cipla.json